Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8584529 | 1.00 | ALDH1A1 (0.42) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL3733817 | 0.98 | ADRB2 (0.41) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL2835530 | 0.94 | ALDH1A1 (0.41) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL9035818 | 0.94 | SMN1; SMN2 (0.38) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL9776380 | 0.93 | ALDH1A1 (0.41) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL11041022 | 0.92 | ALDH1A1 (0.39) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL11037986 | 0.91 | ALDH1A1 (0.38) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL6247312 | 0.90 | MAPT (0.33) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL42565 | 0.88 | ALDH1A1 (0.45) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A | |
| SCHEMBL8582641 | 0.88 | ALDH1A1 (0.45) | ALDH1A1ADRB2ADRB1ADRB3FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999482-A2 | PRODRUGS AND DRUGS | Biogen MA Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-7829580-B2 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1919290-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI Biosciences, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6511965-B2 | For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | SANKYO COMPANY, LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| US-20020137791-A1 | NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6451766-B1 | SIALIDASE INHIBITORS; INFLUENZA VIRICIDES | SANKYO COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6340702-B1 | SIALIDASE INHIBITORS; ANTIVIRAL COMPOUNDS | SANKYO COMPANY, LIMITED (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1152007-A1 | ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001002413-A1 | BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY | INSTITUTO BIOMAR S.A. (ES) | 2001-01-11 | — | — | WO | disclosed |
| EP-0934939-A1 | NEURAMINIC ACID COMPOUNDS | Sankyo Company, Limited (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| US-4477447-A | ANTIBIOTIC, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137791-A1 | NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE | NEU1, NEU3, NEU2 | ALDH1A1 660/4885ADRB2 370/4885ADRB1 185/4885 |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | ALDH1A1 1514/4885ADRB2 4511/4885ADRB1 4361/4885 |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | MSR1, ELOVL1, FFAR1 | ALDH1A1 358/4885ADRB2 1845/4885ADRB1 952/4885 |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | ALDH1A1 2601/4885ADRB2 1603/4885ADRB1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.